You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,843,356


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,843,356
Title:Computer systems and methods for associating genes with traits using cross species data
Abstract: A method for confirming the association of a query QTL or a query gene in the genome of a second species with a clinical trait T exhibited by the second species. A first QTL or a first gene in a first species that is linked to a trait T\' is found. The trait T\' is indicative of trait T. A region of the genome of the first species that comprises the first QTL or the first gene is mapped to a particular region of the genome of the second species. A query QTL or a query gene in the second species that is potentially associated with the trait T is found. The potential association of the query QTL or the query gene with the clinical trait T is confirmed when the query QTL or the query gene is in the particular region of the genome of the second species.
Inventor(s): Schadt; Eric E. (Kirkland, WA), Lamb; John (Shoreline, WA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:10/540,405
Patent Claims:1. A method of identifying a molecular target for a second trait in a second species, the method comprising: (a) identifying a first gene in a segregating population that is causal for a first trait exhibited by all or a portion of said segregating population, wherein each member of said segregating population is a member of a first species and wherein said second trait in said second species corresponds to said first trait in said first species, comprising: (i) identifying a test gene in said first species that has at least one abundance quantitative trait locus (eQTL) coincident with a respective clinical quantitative trait locus (cQTL) for said first trait; and (ii) testing, for one or more respective eQTL in said at least one eQTL, whether the genetic variation of said eQTL across said segregating population and the variation of the first trait across said segregating population are correlated conditional on an abundance pattern of the test gene across said segregating population, wherein, when the genetic variation of (1) said one or more respective eQTL tested in step (ii) and (2) the variation of the first trait across said segregating population are correlated conditional on an abundance pattern of the test gene across said segregating population, said test gene is identified as said first gene; (b) obtaining a biological sample from members of said second species and mapping said first gene in said first species to a corresponding locus in the genome of the second species; and (c) determining whether a marker or a haplotype in said corresponding locus in the genome of the second species associates with said second trait, wherein, when said marker or said haplotype associates with said second trait in said second species, said locus is identified as said molecular target for said second trait, wherein steps (a) and (b) are performed by a suitably programmed computer having a computer program comprising a clustering module for clustering eQTL data from a plurality of eQTL analysis to form a eQTL locus interaction map and an analysis module for analyzing said eQTL interaction map to identify a locus in the genome of the second species that is associated with the second trait that corresponds to the first trait exhibited by the first species.

2. The method of claim 1 wherein said marker or said haplotype is in a second gene in said corresponding locus and said second gene is identified as said molecular target.

3. The method of claim 2 wherein said first gene and said second gene are orthologous.

4. The method of claim 1 wherein said second species is mammalian.

5. The method of claim 1 wherein said second species is human.

6. The method of claim 1 wherein said second trait is asthma, ataxia telangiectasia, bipolar disorder, cancer, common late-onset Alzheimer's disease, diabetes, heart disease, hereditary early-onset Alzheimer's disease, hereditary nonpolyposis colon cancer, hypertension, infection, maturity-onset diabetes of the young, mellitus, migraine, nonalcoholic fatty liver, nonalcoholic steatohepatitis, non-insulin-dependent diabetes mellitus, obesity, polycystic kidney disease, psoriases, schizophrenia, or xeroderma pigmentosum.

7. The method of claim 1 wherein said molecular target is a gene.

8. The method of claim 1 wherein said molecular target is an exon, an intron, or a regulatory element of a gene.

9. The method of claim 1 wherein said marker is a single nucleotide polymorphism, a microsatellite marker, a restriction fragment length polymorphism, a short tandem repeat, a DNA methylation marker, a sequence length polymorphism, a random amplified polymorphic DNA, an amplified fragment length polymorphisms, or a simple sequence repeat.

10. A method of identifying a molecular target for a second trait in a second species, the method comprising: (a) identifying a first gene in biological samples obtained from a segregating population that is causal for a first trait exhibited by all or a portion of said segregating population, wherein each member of said segregating population is a member of a first species and wherein said second trait in said second species corresponds to said first trait in said first species, comprising: (i) identifying a test gene in said first species that has at least one abundance quantitative trait locus (eQTL) coincident with a respective clinical quantitative trait locus (cQTL) for said first trait; and (ii) testing, for one or more respective eQTL in said at least one eQTL, whether the genetic variation of said eQTL across said segregating population and the variation of the first trait across said segregating population are correlated conditional on an abundance pattern of the test gene across said segregating population, wherein, when the genetic variation of (1) said one or more respective eQTL tested in step (ii) and (2) the variation of the first trail across said segregating population are correlated conditional on an abundance pattern of the test gene across said segregating population, said test gene is identified as said first gene; (b) identifying in a biological sample obtained from members of said second species a locus in the genome of the second species that is (1) linked to said second trait and (2) maps to the position in the genome of said first species where said first gene resides; and (c) determining whether a marker or a haplotype in said corresponding locus in the genome of the second species associates with said second trait, wherein, when said marker or said haplotype associates with said second trait in said second species, said locus is identified as said molecular target for said second trait, wherein steps (a) and (b) are performed by a suitably programmed computer having a computer program comprising a clustering module for clustering eQTL data from a plurality of eQTL analysis to form a eQTL locus interaction map and an analysis module for analyzing said eQTL interaction map to identify a locus in the genome of the second species that is linked with the second trait that corresponds to the first trait exhibited by the first species.

11. The method of claim 10 wherein said marker or said haplotype is in a second gene in said corresponding locus and said second gene is identified as said molecular target.

12. The method of claim 11 wherein said first gene and said second gene are orthologous.

13. The method of claim 10 wherein said second species is mammalian.

14. The method of claim 10 wherein said second species is human.

15. The method of claim 10 wherein said second trait is asthma, ataxia telangiectasia, bipolar disorder, cancer, common late-onset Alzheimer's disease, diabetes, heart disease, hereditary early-onset Alzheimer's disease, hereditary nonpolyposis colon cancer, hypertension, infection, maturity-onset diabetes of the young, mellitus, migraine, nonalcoholic fatty liver, nonalcoholic steatohepatitis, non-insulin-dependent diabetes mellitus, obesity, polycystic kidney disease, psoriases, schizophrenia, or xeroderma pigmentosum.

16. The method of claim 10 wherein said molecular target is a gene.

17. The method of claim 10 wherein said molecular target is an exon, an intron, or a regulatory element of a gene.

18. The method of claim 10 wherein said marker is a single nucleotide polymorphism, a microsatellite marker, a restriction fragment length polymorphism, a short tandem repeat, a DNA methylation marker, a sequence length polymorphism, a random amplified polymorphic DNA, an amplified fragment length polymorphisms, or a simple sequence repeat.

19. A method of identifying a molecular target for a second trait in a second species, the method comprising: (a) identifying a first gene in a segregating population that is causal for a first trait exhibited by all or a portion of said segregating population, wherein each member of said segregating population is a member of a first species and wherein said second trait in said second species corresponds to said first trait in said first species, comprising: (i) identifying a test gene in said first species that has at least one abundance quantitative trait locus (eQTL) coincident with a respective clinical quantitative trait locus (cQTL) for said first trait; and (ii) testing, for one or more respective cQTL in said at least one eQTL, whether the genetic variation of said eQTL across said segregating population and the variation of the first trait across said segregating population are correlated conditional on an abundance pattern of the test gene across said segregating population, wherein, when the genetic variation of (1) said one or more respective eQTL tested in step (ii) and (2) the variation of the first trait across said segregating population are correlated conditional on an abundance pattern of the test ene across said segregating population, said test gene is identified as said first gene; and (b) obtaining biological samples from members of a second species and (c) identifying a second gene in the genome of the second species that is orthologous to said first gene and in which (i) the variation of the abundance of the second gene across biological samples taken from a plurality of members of said second species and (ii) the variation of the second trait across said plurality of members of said second species are associated, wherein said second gene is identified as said molecular target for said second trait, wherein steps (a) and (c) are performed by a suitably programmed computer having a computer program comprising a clustering module for clustering eQTL data from a plurality of eQTL analysis to form an eQTL locus interaction map and an analysis module for analyzing said eQTL interaction map to identify a gene in the genome of the second species that is orthologous to said first gene.

20. The method of claim 19, the method further comprising: validating said second gene by determining whether a marker or a haplotype in said second gene associates with said second trait, wherein, when said marker or said haplotype associates with said second trait in said second species, said second gene is validated.

21. The method of claim 19 wherein said second species is mammalian.

22. The method of claim 19 wherein said second species is human.

23. The method of claim 19 wherein said second trait is asthma, ataxia telangiectasia, bipolar disorder, cancer, common late-onset Alzheimer's disease, diabetes, heart disease, hereditary early-onset Alzheimer's disease, hereditary nonpolyposis colon cancer, hypertension, infection, maturity-onset diabetes of the young, mellitus, migraine, nonalcoholic fatty liver, nonalcoholic steatohepatitis, non-insulin-dependent diabetes mellitus, obesity, polycystic kidney disease, psoriases, schizophrenia, or xeroderma pigmentosum.

24. The method of claim 20 wherein said marker is a single nucleotide polymorphism, a microsatellite marker, a restriction fragment length polymorphism, a short tandem repeat, a DNA methylation marker, a sequence length polymorphism, a random amplified polymorphic DNA, an amplified fragment length polymorphisms, or a simple sequence repeat.

Details for Patent 8,843,356

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2022-12-27
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2022-12-27
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2022-12-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.